Dr. med. Dieter Köberle
Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes
Burmeister K, Tornillo L, Piscuoglio S, Ng C, Köberle D, Lehmann F, Moosmann P, Horber D, Jochum W, Grobholz R, Perrina V, Matter M, Eppenberger-Castori S, Andreozzi M, Quagliata L, Terracciano L. Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. PloS one 2017; 12:e0175563.
12.04.2017Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes
12.04.2017PloS one 2017; 12:e0175563
Burmeister Katharina, Tornillo Luigi, Piscuoglio Salvatore, Ng Charlotte K Y, Köberle Dieter, Lehmann Frank, Moosmann Peter, Horber Daniel, Jochum Wolfram, Grobholz Rainer, Perrina Valeria, Matter Matthias S, Eppenberger-Castori Serenella, Andreozzi Mariacarla, Quagliata Luca, Terracciano Luigi M
[Malignant hypoglycaemia]
Rigger J, Kleger G, Semela D, Doenecke C, Rodriguez R, Meyenberger C, Köberle D, Sawatzki M. [Malignant hypoglycaemia]. Praxis (Bern 1994) 2014; 103:399-403.
26.03.2014[Malignant hypoglycaemia]
26.03.2014Praxis (Bern 1994) 2014; 103:399-403
Rigger Johannes, Kleger Gian-Reto, Semela David, Doenecke Christian, Rodriguez Regulo, Meyenberger Christa, Köberle Dieter, Sawatzki Mikael
Maligne Hypoglykämie
Rigger J, Kleger G, Semela D, Doenecke C, Rodriguez R, Meyenberger C, Köberle D, Sawatzki M. Maligne Hypoglykämie. Praxis 2014; 103 (7):399-403.
01.02.2014Maligne Hypoglykämie
01.02.2014Praxis 2014; 103 (7):399-403
Rigger Johannes, Kleger Gian Reto, Semela David, Doenecke Christian, Rodriguez Regulo, Meyenberger Christa, Köberle Dieter, Sawatzki Mikael
Perioperative Blood Transfusions Do Not Impact Overall and Disease-Free Survival After Curative Rectal Cancer Resection: A Propensity Score Analysis
Warschkow R, Gueller U, Köberle D, Mueller S, Steffen T, Thurnheer M, Schmied B, Tarantino I. Perioperative Blood Transfusions Do Not Impact Overall and Disease-Free Survival After Curative Rectal Cancer Resection: A Propensity Score Analysis. Ann Surg 2013; 259:131-138.
06.03.2013Perioperative Blood Transfusions Do Not Impact Overall and Disease-Free Survival After Curative Rectal Cancer Resection: A Propensity Score Analysis
06.03.2013Ann Surg 2013; 259:131-138
Warschkow Rene, Gueller Ulrich, Köberle Dieter, Mueller Sascha, Steffen Thomas, Thurnheer Martin, Schmied Bruno, Tarantino Ignazio
Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07
Helbling D, Bougel S, Leibundgut E, Benhattar J, Yan P, Baertschi D, Borner M, Widmer L, Saletti P, Rauch D, Madlung A, Winterhalder R, Burkhard R, Gloor B, Bosman F, Sun H, Gautschi O, Bodoky G, Köberle D. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol 2012; 24:718-25.
08.11.2012Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07
08.11.2012Ann Oncol 2012; 24:718-25
Helbling D, Bougel S, Leibundgut E O, Benhattar J, Yan P, Baertschi D, Borner M, Widmer L, Saletti P, Rauch D, Madlung A, Winterhalder R, Burkhard R, Gloor B, Bosman F, Sun H, Gautschi O, Bodoky G, Köberle Dieter
Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
Blum D, Köberle D, Ribi K, Hsu Schmitz S, Uitger U, Klingbiel D, Strasser F. Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC. BMC Palliat Care 2012; 11:19.
24.09.2012Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
24.09.2012BMC Palliat Care 2012; 11:19
Blum David, Köberle Dieter, Ribi Karin, Hsu Schmitz Shu-Fang, Uitger Urs, Klingbiel Dirk, Strasser Florian
Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients
Tarantino I, Cerny T, Steffen T, Mueller S, Schmied B, Köberle D, Merati-Kashani K, Worni M, Warschkow R, Gueller U. Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients. Br J Cancer 2012; 107:266-74.
26.06.2012Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients
26.06.2012Br J Cancer 2012; 107:266-74
Tarantino Ignazio, Cerny Thomas, Steffen Thomas, Mueller Sascha, Schmied B M, Köberle Dieter, Merati-Kashani K, Worni M, Warschkow Rene, Gueller Ulrich
Peri-operative blood transfusions do not impact overall and disease-free survival after curative rectal cancer resection. A propensity score analysis
Warschkow R, Gueller U, Köberle D, Müller S, Steffen T, Thurnherr M, Schmied B, Tarantino I. Peri-operative blood transfusions do not impact overall and disease-free survival after curative rectal cancer resection. A propensity score analysis. Annals of surgery 2012
01.01.2012Peri-operative blood transfusions do not impact overall and disease-free survival after curative rectal cancer resection. A propensity score analysis
01.01.2012Annals of surgery 2012
Warschkow R, Gueller Ulrich, Köberle Dieter, Müller SA, Steffen T, Thurnherr M, Schmied B, Tarantino I
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma
Saletti P, Sessa C, De Dosso S, Cerny T, Renggli V, Köberle D. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. Oncology 2011; 81:50-4.
15.09.2011Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma
15.09.2011Oncology 2011; 81:50-4
Saletti Piercarlo, Sessa Cristiana, De Dosso Sara, Cerny Thomas, Renggli Verena, Köberle Dieter
Langerhans cell histiocytosis with central nervous system involvement-complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib
Baumann M, Cerny T, Sommacal A, Köberle D. Langerhans cell histiocytosis with central nervous system involvement-complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib. Hematol Oncol 2011
05.07.2011Langerhans cell histiocytosis with central nervous system involvement-complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib
05.07.2011Hematol Oncol 2011
Baumann Michael, Cerny Thomas, Sommacal Andreas, Köberle Dieter
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
Köberle D, Thürlimann B, Pilop C, Crowe S, Öhlschlegel C, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr Relat Cancer 2011; 18:257-64.
09.03.2011Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
09.03.2011Endocr Relat Cancer 2011; 18:257-64
Köberle Dieter, Thürlimann Beat, Pilop C, Crowe S, Öhlschlegel Christian, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)
Recent advances and future challenges in the treatment of hepatocellular and biliary tract carcinomas
Köberle D, Samaras P. Recent advances and future challenges in the treatment of hepatocellular and biliary tract carcinomas. Memo 4 2011; 4:94-97.
01.01.2011Recent advances and future challenges in the treatment of hepatocellular and biliary tract carcinomas
01.01.2011Memo 4 2011; 4:94-97
Köberle Dieter, Samaras P
Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates
Jörger M, Templeton A, Köberle D, Engler H, Riesen W, Thürlimann B. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Cancer Chemother Pharmacol 2010
04.08.2010Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates
04.08.2010Cancer Chemother Pharmacol 2010
Jörger Markus, Templeton Arnoud, Köberle Dieter, Engler H, Riesen W F, Thürlimann Beat
Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02)
Ruhstaller T, Köberle D, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos R, Thierstein S, Borner M, Schuller J, Ribi K, Templeton A, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie 2010; 33:222-8.
01.01.2010Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02)
01.01.2010Onkologie 2010; 33:222-8
Ruhstaller Thomas, Köberle Dieter, von Briel Christian, Lombriser Norbert, Lohri Andreas, Pederiva Stefanie, von Moos Roger, Thierstein Sandra, Borner Markus, Schuller Jan C, Ribi Karin, Templeton Arnoud, Popescu Razvan
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03)
von Moos R, Lanz D, Simcock M, Köberle D, Cathomas R, Uhlmann C, Widmer L, Ruhstaller T, Roth A, Popescu R. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). Onkologie 2010; 33:295-9.
01.01.2010Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03)
01.01.2010Onkologie 2010; 33:295-9
von Moos Roger, Lanz Doris, Simcock Mathew, Köberle Dieter, Cathomas Richard, Uhlmann Catrina, Widmer Lucas, Ruhstaller Thomas, Roth Arnaud, Popescu Razvan
Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer
Ruhstaller T, Köberle D, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos R, Thierstein S, Borner M, Schuller J, Ribi K, Templeton A, Popescu R. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer. Onkologie 2010; 33:222-228.
01.01.2010Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer
01.01.2010Onkologie 2010; 33:222-228
Ruhstaller Thomas, Köberle Dieter, von Briel C, Lombriser N, Lohri A, Pederiva S, von Moos Roger, Thierstein S, Borner M, Schuller J C, Ribi K, Templeton Arnoud, Popescu R
Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02)
Klaeser B, Ruhstaller T, von Moos R, Albrecht S, Caspar C, Pestalozzi B, Zünd M, Brauchli P, Cescato-Wenger C, Hany T, Balmer-Majno S, Widmer L, Köberle D, Schuller J, Nitzsche E, Lange J. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie 2009; 32:724-30.
01.12.2009Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02)
01.12.2009Onkologie 2009; 32:724-30
Klaeser Bernd, Ruhstaller Thomas, von Moos Roger, Albrecht Susanne, Caspar Clemens, Pestalozzi Bernhard C, Zünd Michael, Brauchli Peter, Cescato-Wenger Corinne, Hany Thomas, Balmer-Majno Sabine, Widmer Lucas, Köberle Dieter, Schuller Jan C, Nitzsche Egbert, Lange Jochen
Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Cathomas R, Köberle D, Ruhstaller T, Mayer G, Räss A, Mey U, von Moos R. Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009
12.09.2009Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
12.09.2009Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009
Cathomas Richard, Köberle Dieter, Ruhstaller Thomas, Mayer Gisela, Räss Andrea, Mey Ulrich, von Moos Roger
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
Ruhstaller T, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle D, Balmermajno S, Pestalozzi B, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J, Widmer L, Swiss Group for Clinical Cancer Research (SAKK). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1522-8.
01.09.2009Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)
01.09.2009Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009; 20:1522-8
Ruhstaller Thomas, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle Dieter, Balmermajno S, Pestalozzi B C, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J C, Widmer L, Swiss Group for Clinical Cancer Research (SAKK)
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
Ribi K, Pestalozzi B, Lombriser N, Borner M, von Moos R, Moosmann P, Hess V, Roth A, Honegger H, Schuller J, Köberle D, Ruhstaller T. Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009; 17:1109-1116.
07.02.2009Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
07.02.2009Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2009; 17:1109-1116
Ribi Karin, Pestalozzi Bernhard, Lombriser Norbert, Borner Markus, von Moos Roger, Moosmann Peter, Hess Viviane, Roth Arnaud, Honegger Hanspeter, Schuller Jan C, Köberle Dieter, Ruhstaller Thomas